2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China
Location status: Recruiting
Recruiting
NCT Number: NCT04924998
Clinical Study for AL-CM
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
Recruiting
Interested in participating?
Request InfoKey information
Age range
18 year–80 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
- Patients have the ability to understand the test, can cooperate with investigators.
Exclusion criteria
- Unable to understand or unwilling to fill in informed consent forms or follow visitors
Treatment and study plan
current treatment of AL-CM
Drugcurrent treatment of AL-CM
Primary outcomes
-
Primary Outcome
Time frame: 10 year
incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina)
Sponsors and collaborators
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
Registry information
Official study title
Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy
Important dates
- Study start
- 2021
- Primary completion
- 2031
- Study completion
- 2031
- First posted
- Jun 14, 2021
- Registry last updated
- Jan 31, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.